The Experts below are selected from a list of 13512 Experts worldwide ranked by ideXlab platform

Shlomo Melmed - One of the best experts on this subject based on the ideXlab platform.

  • Opposing effects of pituitary Leukemia Inhibitory Factor and SOCS-3 on the ACTH axis response to inflammation
    American Journal of Physiology-endocrinology and Metabolism, 2002
    Co-Authors: Vera Chesnokova, Anastasia Kariagina, Shlomo Melmed
    Abstract:

    We have shown that Leukemia Inhibitory Factor (LIF) and suppressor of cytokine signaling (SOCS)-3 are expressed in the hypothalamus and pituitary and that LIF induces proopiomelanocortin (POMC) and...

  • Leukemia Inhibitory Factor neuroimmune modulator of endocrine function
    Endocrine Reviews, 2000
    Co-Authors: C J Auernhammer, Shlomo Melmed
    Abstract:

    Leukemia-Inhibitory Factor (LIF) is a pleiotropic cytokine expressed by multiple tissue types. The LIF receptor shares a common gp130 receptor subunit with the IL-6 cytokine superfamily. LIF signaling is mediated mainly by JAK-STAT (janus-kinase-signal transducer and activator of transcription) pathways and is abrogated by the SOCS (suppressor-of cytokine signaling) and PIAS (protein inhibitors of activated STAT) proteins. In addition to classic hematopoietic and neuronal actions, LIF plays a critical role in several endocrine functions including the utero-placental unit, the hypothalamo-pituitary-adrenal axis, bone cell metabolism, energy homeostasis, and hormonally responsive tumors. This paper reviews recent advances in our understanding of molecular mechanisms regulating LIF expression and action and also provides a systemic overview of LIF-mediated endocrine regulation. Local and systemic LIF serve to integrate multiple developmental and functional cell signals, culminating in maintaining appropriate...

  • Expression of Leukemia Inhibitory Factor in craniopharyngioma.
    Endocrine Pathology, 1999
    Co-Authors: Ami Tran, Kalman Kovacs, Lucia Stefaneanu, George Kontogeorgos, Bernd W. Scheithauer, Shlomo Melmed
    Abstract:

    It has recently been reported that overexpression of Leukemia Inhibitory Factor (LIF) in mice transgenic for LIF causes invagination of the anterior wall of Rathke’s pouch leading to the formation of cysts lined by LIF immunoreactive epithelial cells. Strong immunoreactivity was also found in human Rathke’s cleft cysts. Because such cysts and craniopharyngiomas share a common histogenesis, we raised the question of whether LIF is also expressed in craniopharyngioma.

Michael R Roberts - One of the best experts on this subject based on the ideXlab platform.

  • Leukemia Inhibitory Factor lif dependent pluripotent stem cells established from inner cell mass of porcine embryos
    Journal of Biological Chemistry, 2011
    Co-Authors: Bhanu Prakash V L Telugu, Toshihiko Ezashi, Sunilima Sinha, Andrei P Alexenko, Lee D Spate, Randall S Prather, Michael R Roberts
    Abstract:

    The pig is important for agriculture and as an animal model in human and veterinary medicine, yet despite over 20 years of effort, there has been a failure to generate pluripotent stem cells analogous to those derived from mouse embryos. Here we report the production of Leukemia Inhibitory Factor-dependent, so-called naive type, pluripotent stem cells from the inner cell mass of porcine blastocysts by up-regulating expression of KLF4 and POU5F1. The alkaline phosphatase-positive colonies resulting from reprogramming resemble mouse embryonic stem cells in colony morphology, cell cycle interval, transcriptome profile, and expression of pluripotent markers, such as POU5F1, SOX2, and surface marker SSEA1. They are dependent on Leukemia Inhibitory Factor signaling for maintenance of pluripotency, can be cultured over extended passage, and have the ability to form teratomas. These cells derived from the inner cell mass of pig blastocysts are clearly distinct from the FGF2-dependent "primed" induced pluripotent stem cells described recently from porcine mesenchymal cells. The data are consistent with the hypothesis that the up-regulation of KLF4, as well as POU5F1, is required to create and stabilize the naive pluripotent state and may explain why the derivation of embryonic stem cells from pigs and other ungulates has proved so difficult.

Michael J K Harper - One of the best experts on this subject based on the ideXlab platform.

  • Leukemia Inhibitory Factor Leukemia Inhibitory Factor receptor and glycoprotein 130 in rhesus monkey uterus during menstrual cycle and early pregnancy
    Biology of Reproduction, 2000
    Co-Authors: Zengming Yang, Shijie Li, Hongbin Wang, Michael J K Harper
    Abstract:

    This goal of this study was to examine immunohistochemical distribution of Leukemia Inhibitory Factor (LIF), LIF receptor (LIFR), and glycoprotein (gp) 130 in rhesus monkey uterus during the menstrual cycle and early pregnancy. Pregnancy rate was significantly reduced in the control group from 66.7% (12 of 18) to 22.2% (4 of 18) with an injection of goat anti-human recombinant LIF immunoglobulin G into the uterine lumen on Day 8 of pregnancy. LIF was mainly localized in glandular and luminal epithelium. LIF immunostaining during the luteal phase was stronger than it was during the proliferative phase. LIF staining gradually increased from Day 3 of pregnancy and reached its highest level on Day 9. LIFR was mainly localized in the glandular and luminal epithelium. LIFR staining during the luteal phase was stronger than it was during the proliferative phase. LIFR staining began to increase from Day 3 of pregnancy and reached a high level on Days 9 and 11. Gp130, a signal-transducing receptor component of LIF, was mainly localized in the glandular epithelium. A high level of gp130 was found on Days 16 and 20 of menstrual cycle, and from Days 5 to 11 of pregnancy. These results suggest that LIF may play an important role in monkey implantation, as it does in mice.

Bhanu Prakash V L Telugu - One of the best experts on this subject based on the ideXlab platform.

  • Leukemia Inhibitory Factor lif dependent pluripotent stem cells established from inner cell mass of porcine embryos
    Journal of Biological Chemistry, 2011
    Co-Authors: Bhanu Prakash V L Telugu, Toshihiko Ezashi, Sunilima Sinha, Andrei P Alexenko, Lee D Spate, Randall S Prather, Michael R Roberts
    Abstract:

    The pig is important for agriculture and as an animal model in human and veterinary medicine, yet despite over 20 years of effort, there has been a failure to generate pluripotent stem cells analogous to those derived from mouse embryos. Here we report the production of Leukemia Inhibitory Factor-dependent, so-called naive type, pluripotent stem cells from the inner cell mass of porcine blastocysts by up-regulating expression of KLF4 and POU5F1. The alkaline phosphatase-positive colonies resulting from reprogramming resemble mouse embryonic stem cells in colony morphology, cell cycle interval, transcriptome profile, and expression of pluripotent markers, such as POU5F1, SOX2, and surface marker SSEA1. They are dependent on Leukemia Inhibitory Factor signaling for maintenance of pluripotency, can be cultured over extended passage, and have the ability to form teratomas. These cells derived from the inner cell mass of pig blastocysts are clearly distinct from the FGF2-dependent "primed" induced pluripotent stem cells described recently from porcine mesenchymal cells. The data are consistent with the hypothesis that the up-regulation of KLF4, as well as POU5F1, is required to create and stabilize the naive pluripotent state and may explain why the derivation of embryonic stem cells from pigs and other ungulates has proved so difficult.

Stephanie M. Davis - One of the best experts on this subject based on the ideXlab platform.

  • The role of the Leukemia Inhibitory Factor receptor in neuroprotective signaling.
    Pharmacology & Therapeutics, 2017
    Co-Authors: Stephanie M. Davis, Keith R. Pennypacker
    Abstract:

    Abstract Several neurotropic cytokines relay their signaling through the Leukemia Inhibitory Factor receptor. This 190 kDa subunit couples with the 130 kDa gp130 subunit to transduce intracellular signaling in neurons and oligodendrocytes that leads to expression of genes associated with neurosurvival. Moreover, activation of this receptor alters the phenotype of immune cells to an anti-inflammatory one. Although cytokines that activate the Leukemia Inhibitory Factor receptor have been studied in the context of neurodegenerative disease, therapeutic targeting of the specific receptor subunit has been understudied in by comparison. This review examines the role of this receptor in the CNS and immune system, and its application in the treatment in stroke and other brain pathologies.

  • Abstract TP271: Leukemia Inhibitory Factor Differentially Regulates Its Receptor in the Brain and Immune System After Stroke
    Stroke, 2017
    Co-Authors: Stephanie M. Davis, Lisa A. Collier, Jawad A. Fazal, Michael Britton, Christopher C. Leonardo, Craig T. Ajmo, Keith R. Pennypacker
    Abstract:

    Objective: To identify how Leukemia Inhibitory Factor (LIF) regulates antioxidant neuroprotective and anti-inflammatory signaling through the expression and trafficking of its receptor (LIFR). Hypo...

  • Leukemia Inhibitory Factor as a Neuroprotective Agent against Focal Cerebral Ischemia
    2016
    Co-Authors: Stephanie M. Davis
    Abstract:

    xi CHAPTER 1: INTRODUCTION 1 Stroke Overview 1 Stroke as a Worldwide Health Problem 1 Risk Factors for Stroke 1 Types of Stroke 2 Animal Models of Ischemic Stroke 2 Current Treatments for Ischemic Stroke 3 Thrombolytic Therapy 3 Cellular Treatment 4 Other Therapies .5 Phases of Stroke Pathophysiology 6 Acute Cytotoxic Injury 6 Delayed Neuroinflammation 7 Role of the Spleen 7 Oxidative Stress 8 Production of Reactive Oxygen Species 8 Failure of Exogenous Antioxidants 9 Endogenous Antioxidant Protection 10 Glutathione Metabolism 10 Peroxiredoxins 12 Catalase 13 Superoxide Dismutase 13 SOD Isoforms 13 SOD Enzymes as Stroke Targets 14 Transcription Factors 15 Upregulation of Protective Genes 15 Myeloid Zinc Finger-1 16 Specificity Protein 1 17 Leukemia Inhibitory Factor 19 Discovery of LIF 19 LIF Signaling 19 Clinical Trials 20 LIF in Nervous System Development 20 Treatment of Neurodegenerative Disease 21 ii Immunomodulation by LIF 22 LIF as a Neuroprotective Stroke Therapeutic 24 References 25 CHAPTER 2: Leukemia Inhibitory Factor PROTECTS NEURONS FROM ISCHEMIC DAMAGE VIA UPREGULATION OF SUPEROXIDE DISMUTASE 3 40 Note to Reader 40 Abstract 40